Barclays PLC Raises Stock Holdings in Zura Bio Limited (NASDAQ:ZURA)

Barclays PLC increased its position in Zura Bio Limited (NASDAQ:ZURA) by 777.1% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 64,061 shares of the company’s stock after acquiring an additional 56,757 shares during the period. Barclays PLC owned approximately 0.10% of Zura Bio worth $260,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Point72 Asset Management L.P. purchased a new position in shares of Zura Bio during the 2nd quarter valued at about $8,446,000. Armistice Capital LLC increased its stake in shares of Zura Bio by 53.2% in the 2nd quarter. Armistice Capital LLC now owns 2,524,000 shares of the company’s stock valued at $8,834,000 after purchasing an additional 876,000 shares in the last quarter. The Manufacturers Life Insurance Company purchased a new position in shares of Zura Bio in the 3rd quarter valued at about $71,000. Braidwell LP purchased a new position in shares of Zura Bio in the 3rd quarter valued at about $10,040,000. Finally, Great Point Partners LLC increased its stake in shares of Zura Bio by 68.3% in the 2nd quarter. Great Point Partners LLC now owns 4,642,241 shares of the company’s stock valued at $16,248,000 after purchasing an additional 1,884,501 shares in the last quarter. Hedge funds and other institutional investors own 61.14% of the company’s stock.

Analysts Set New Price Targets

Several equities analysts recently weighed in on the company. Cantor Fitzgerald restated an “overweight” rating on shares of Zura Bio in a research note on Wednesday, December 11th. Chardan Capital lowered their price objective on Zura Bio from $14.00 to $12.00 and set a “buy” rating on the stock in a report on Friday, November 8th. Piper Sandler reiterated an “overweight” rating and issued a $26.00 price objective on shares of Zura Bio in a report on Thursday, September 19th. Leerink Partnrs upgraded Zura Bio to a “strong-buy” rating in a report on Monday, November 4th. Finally, Leerink Partners initiated coverage on Zura Bio in a report on Monday, November 4th. They issued an “outperform” rating and a $15.00 price objective on the stock. One investment analyst has rated the stock with a hold rating, five have given a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, Zura Bio currently has a consensus rating of “Buy” and a consensus target price of $15.80.

Zura Bio Stock Performance

Shares of Zura Bio stock opened at $2.58 on Monday. The stock’s 50 day simple moving average is $3.15 and its 200-day simple moving average is $3.60. Zura Bio Limited has a 1-year low of $2.00 and a 1-year high of $6.35.

Zura Bio (NASDAQ:ZURA) last released its quarterly earnings results on Thursday, November 7th. The company reported ($0.26) EPS for the quarter, missing the consensus estimate of ($0.14) by ($0.12). On average, equities analysts expect that Zura Bio Limited will post -0.65 EPS for the current year.

Insider Activity

In other news, Director Parvinder Thiara sold 1,001,633 shares of Zura Bio stock in a transaction that occurred on Monday, November 25th. The shares were sold at an average price of $2.73, for a total transaction of $2,734,458.09. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Corporate insiders own 22.10% of the company’s stock.

Zura Bio Company Profile

Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops Tibulizumab, an IgG-scFv bispecific dual-antagonist antibody engineered by the fusion of ixekizumab and tabalumab that neutralizes IL-17A and BAFF, which is in Phase 2 clinical trial development; ZB-168, a monoclonal antibody that binds and neutralizes the IL-7 receptor chain that impact on diseases driven by IL7 and thymic stromal lymphopoietin immune pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development.